ID   FMO3_HUMAN              Reviewed;         532 AA.
AC   P31513; B2R816; Q14854; Q8N5N5;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 5.
DT   12-APR-2017, entry version 176.
DE   RecName: Full=Dimethylaniline monooxygenase [N-oxide-forming] 3;
DE            EC=1.14.13.8;
DE   AltName: Full=Dimethylaniline oxidase 3;
DE   AltName: Full=FMO II;
DE   AltName: Full=FMO form 2;
DE   AltName: Full=Hepatic flavin-containing monooxygenase 3;
DE            Short=FMO 3;
DE   AltName: Full=Trimethylamine monooxygenase;
DE            EC=1.14.13.148;
GN   Name=FMO3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=1542660; DOI=10.1073/pnas.89.5.1685;
RA   Lomri N., Gu Q., Cashman J.R.;
RT   "Molecular cloning of the flavin-containing monooxygenase (form II)
RT   cDNA from adult human liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:1685-1689(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8654418; DOI=10.1111/j.1432-1033.1996.00683.x;
RA   Dolphin C.T., Cullingford T.E., Shephard E.A., Smith R.L.,
RA   Phillips I.R.;
RT   "Differential developmental and tissue-specific regulation of
RT   expression of the genes encoding three members of the flavin-
RT   containing monooxygenase family of man, FMO1, FMO3 and FM04.";
RL   Eur. J. Biochem. 235:683-689(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9417913; DOI=10.1006/geno.1997.5031;
RA   Dolphin C.T., Riley J.H., Smith R.L., Shephard E.A., Phillips I.R.;
RT   "Structural organization of the human flavin-containing monooxygenase
RT   3 gene (FMO3), the favored candidate for fish-odor syndrome,
RT   determined directly from genomic DNA.";
RL   Genomics 46:260-267(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-132; LYS-158;
RP   CYS-205; MET-257; ALA-277; GLY-308; PRO-360 AND GLN-362.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-257.
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 2-10, FUNCTION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=9224773;
RA   Haining R.L., Hunter A.P., Sadeque A.J., Philpot R.M., Rettie A.E.;
RT   "Baculovirus-mediated expression and purification of human FMO3:
RT   catalytic, immunochemical, and structural characterization.";
RL   Drug Metab. Dispos. 25:790-797(1997).
RN   [10]
RP   CATALYTIC ACTIVITY, VARIANTS TMAU ILE-66 AND LEU-153, AND VARIANTS
RP   LYS-158; MET-257 AND GLY-308.
RX   PubMed=9536088; DOI=10.1093/hmg/7.5.839;
RA   Treacy E.P., Akerman B.R., Chow L.M.L., Youil R., Bibeau C., Lin J.,
RA   Bruce A.G., Knight M., Danks D.M., Cashman J.R., Forrest S.M.;
RT   "Mutations of the flavin-containing monooxygenase gene (FMO3) cause
RT   trimethylaminuria, a defect in detoxication.";
RL   Hum. Mol. Genet. 7:839-845(1998).
RN   [11]
RP   BIOPHYSICOCHEMICAL PROPERTIES, CHARACTERIZATION OF VARIANTS TMAU
RP   SER-61; ILE-66; LEU-153 AND TRP-492, AND CHARACTERIZATION OF VARIANTS
RP   LYS-158; MET-257 AND GLY-308.
RX   PubMed=17531949; DOI=10.1016/j.abb.2007.04.014;
RA   Yeung C.K., Adman E.T., Rettie A.E.;
RT   "Functional characterization of genetic variants of human FMO3
RT   associated with trimethylaminuria.";
RL   Arch. Biochem. Biophys. 464:251-259(2007).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   VARIANTS TMAU ILE-66 AND TRP-492.
RX   PubMed=10338091;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<376::AID-HUMU5>3.0.CO;2-A;
RA   Akerman B.R., Forrest S.M., Chow L.M.L., Youil R., Knight M.,
RA   Treacy E.P.;
RT   "Two novel mutations of the FMO3 gene in a proband with
RT   trimethylaminuria.";
RL   Hum. Mutat. 13:376-379(1999).
RN   [14]
RP   VARIANTS TMAU THR-52 AND LEU-387, AND VARIANTS LYS-158 AND GLY-308.
RX   PubMed=10479479; DOI=10.1006/mgme.1999.2885;
RA   Akerman B.R., Lemass H., Chow L.M.L., Lambert D.M., Greenberg C.,
RA   Bibeau C., Mamer O.A., Treacy E.P.;
RT   "Trimethylaminuria is caused by mutations of the FMO3 gene in a North
RT   American cohort.";
RL   Mol. Genet. Metab. 68:24-31(1999).
RN   [15]
RP   VARIANTS TMAU SER-61; LEU-153; ILE-434 AND TRP-492, AND
RP   CHARACTERIZATION OF VARIANTS TMAU SER-61; LEU-153; ILE-434 AND
RP   TRP-492.
RX   PubMed=11191884; DOI=10.1097/00008571-200012000-00005;
RA   Dolphin C.T., Janmohamed A., Smith R.L., Shephard E.A., Phillips I.R.;
RT   "Compound heterozygosity for missense mutations in the flavin-
RT   containing monooxygenase 3 (FM03) gene in patients with fish-odour
RT   syndrome.";
RL   Pharmacogenetics 10:799-807(2000).
RN   [16]
RP   VARIANTS HIS-132; LYS-158; MET-257; PRO-360; GLN-362 AND ARG-503.
RX   PubMed=12527699; DOI=10.1124/dmd.31.2.187;
RA   Furnes B., Feng J., Sommer S.S., Schlenk D.;
RT   "Identification of novel variants of the flavin-containing
RT   monooxygenase gene family in African Americans.";
RL   Drug Metab. Dispos. 31:187-193(2003).
RN   [17]
RP   VARIANTS GLU-198 AND CYS-205.
RX   PubMed=15618753; DOI=10.2133/dmpk.18.333;
RA   Fujieda M., Yamazaki H., Togashi M., Saito T., Kamataki T.;
RT   "Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in
RT   Japanese.";
RL   Drug Metab. Pharmacokinet. 18:333-335(2003).
RN   [18]
RP   VARIANT TMAU LYS-32.
RX   PubMed=12893987; DOI=10.1097/00008571-200308000-00007;
RA   Zhang J., Tran Q., Lattard V., Cashman J.R.;
RT   "Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3)
RT   gene causing trimethylaminuria.";
RL   Pharmacogenetics 13:495-500(2003).
RN   [19]
RP   VARIANTS ASP-24; LYS-61; LYS-158; MET-257; GLY-308 AND ASN-416,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION OF VARIANTS
RP   ASP-24; LYS-61 AND ASN-416.
RX   PubMed=17050781; DOI=10.1124/jpet.106.112268;
RA   Koukouritaki S.B., Poch M.T., Henderson M.C., Siddens L.K.,
RA   Krueger S.K., VanDyke J.E., Williams D.E., Pajewski N.M., Wang T.,
RA   Hines R.N.;
RT   "Identification and functional analysis of common human flavin-
RT   containing monooxygenase 3 genetic variants.";
RL   J. Pharmacol. Exp. Ther. 320:266-273(2007).
CC   -!- FUNCTION: Involved in the oxidative metabolism of a variety of
CC       xenobiotics such as drugs and pesticides. It N-oxygenates primary
CC       aliphatic alkylamines as well as secondary and tertiary amines.
CC       Plays an important role in the metabolism of trimethylamine (TMA),
CC       via the production of TMA N-oxide (TMAO). Is also able to perform
CC       S-oxidation when acting on sulfide compounds (PubMed:9224773).
CC       {ECO:0000250|UniProtKB:P97501, ECO:0000269|PubMed:9224773}.
CC   -!- CATALYTIC ACTIVITY: N,N-dimethylaniline + NADPH + O(2) = N,N-
CC       dimethylaniline N-oxide + NADP(+) + H(2)O.
CC       {ECO:0000269|PubMed:9536088}.
CC   -!- CATALYTIC ACTIVITY: N,N,N-trimethylamine + NADPH + O(2) = N,N,N-
CC       trimethylamine N-oxide + NADP(+) + H(2)O.
CC       {ECO:0000269|PubMed:9536088}.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=21 uM for trimethylamine (at pH 8.5)
CC         {ECO:0000269|PubMed:17050781, ECO:0000269|PubMed:17531949};
CC         KM=31 uM for trimethylamine (at pH 7.4 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:17050781, ECO:0000269|PubMed:17531949};
CC         KM=43 uM for benzydamine (at pH 7.4 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:17050781, ECO:0000269|PubMed:17531949};
CC         KM=55.7 uM for ethylenethiourea (at pH 8.5)
CC         {ECO:0000269|PubMed:17050781, ECO:0000269|PubMed:17531949};
CC         KM=71.8 uM for methimazole (at pH 8.5)
CC         {ECO:0000269|PubMed:17050781, ECO:0000269|PubMed:17531949};
CC         KM=150.1 uM for sulindac (at pH 8.5)
CC         {ECO:0000269|PubMed:17050781, ECO:0000269|PubMed:17531949};
CC         KM=248 uM for methyl p-tolyl sulfide (at pH 7.4 and 37 degrees
CC         Celsius) {ECO:0000269|PubMed:17050781,
CC         ECO:0000269|PubMed:17531949};
CC   -!- INTERACTION:
CC       O43889-2:CREB3; NbExp=3; IntAct=EBI-12361463, EBI-625022;
CC   -!- SUBCELLULAR LOCATION: Microsome membrane. Endoplasmic reticulum
CC       membrane.
CC   -!- TISSUE SPECIFICITY: Liver.
CC   -!- DISEASE: Trimethylaminuria (TMAU) [MIM:602079]: Inborn error of
CC       metabolism associated with an offensive body odor and caused by
CC       deficiency of FMO-mediated N-oxidation of amino-trimethylamine
CC       (TMA) derived from foodstuffs. Affected individuals excrete
CC       relatively large amounts of TMA in their urine, sweat, and breath,
CC       and exhibit a fishy body odor characteristic of the malodorous
CC       free amine. {ECO:0000269|PubMed:10338091,
CC       ECO:0000269|PubMed:10479479, ECO:0000269|PubMed:11191884,
CC       ECO:0000269|PubMed:12893987, ECO:0000269|PubMed:17531949,
CC       ECO:0000269|PubMed:9536088}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the FMO family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fmo3/";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=A case for discomfort -
CC       Issue 149 of June 2013;
CC       URL="http://web.expasy.org/spotlight/back_issues/149";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M83772; AAA86284.1; -; mRNA.
DR   EMBL; Z47552; CAA87632.1; -; mRNA.
DR   EMBL; U39967; AAC51932.1; -; Genomic_DNA.
DR   EMBL; U39961; AAC51932.1; JOINED; Genomic_DNA.
DR   EMBL; U39962; AAC51932.1; JOINED; Genomic_DNA.
DR   EMBL; U39963; AAC51932.1; JOINED; Genomic_DNA.
DR   EMBL; U39964; AAC51932.1; JOINED; Genomic_DNA.
DR   EMBL; U39965; AAC51932.1; JOINED; Genomic_DNA.
DR   EMBL; U39966; AAC51932.1; JOINED; Genomic_DNA.
DR   EMBL; AY895830; AAW65372.1; -; Genomic_DNA.
DR   EMBL; AK313197; BAG36013.1; -; mRNA.
DR   EMBL; AL021026; CAA15908.1; -; Genomic_DNA.
DR   EMBL; CH471067; EAW90887.1; -; Genomic_DNA.
DR   EMBL; BC032016; AAH32016.1; -; mRNA.
DR   CCDS; CCDS1292.1; -.
DR   PIR; A38228; A38228.
DR   PIR; S62367; S51130.
DR   RefSeq; NP_001002294.1; NM_001002294.2.
DR   RefSeq; NP_001306102.1; NM_001319173.1.
DR   RefSeq; NP_001306103.1; NM_001319174.1.
DR   RefSeq; NP_008825.4; NM_006894.5.
DR   UniGene; Hs.445350; -.
DR   ProteinModelPortal; P31513; -.
DR   SMR; P31513; -.
DR   IntAct; P31513; 4.
DR   STRING; 9606.ENSP00000356729; -.
DR   ChEMBL; CHEMBL3430864; -.
DR   DrugBank; DB00918; Almotriptan.
DR   DrugBank; DB00501; Cimetidine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00250; Dapsone.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB05294; Vandetanib.
DR   DrugBank; DB00582; Voriconazole.
DR   iPTMnet; P31513; -.
DR   PhosphoSitePlus; P31513; -.
DR   BioMuta; FMO3; -.
DR   DMDM; 6166183; -.
DR   PaxDb; P31513; -.
DR   PeptideAtlas; P31513; -.
DR   PRIDE; P31513; -.
DR   DNASU; 2328; -.
DR   Ensembl; ENST00000367755; ENSP00000356729; ENSG00000007933.
DR   GeneID; 2328; -.
DR   KEGG; hsa:2328; -.
DR   UCSC; uc001ghi.3; human.
DR   CTD; 2328; -.
DR   DisGeNET; 2328; -.
DR   GeneCards; FMO3; -.
DR   GeneReviews; FMO3; -.
DR   HGNC; HGNC:3771; FMO3.
DR   HPA; HPA013750; -.
DR   MalaCards; FMO3; -.
DR   MIM; 136132; gene.
DR   MIM; 602079; phenotype.
DR   neXtProt; NX_P31513; -.
DR   OpenTargets; ENSG00000007933; -.
DR   Orphanet; 35056; Trimethylaminuria.
DR   PharmGKB; PA166; -.
DR   eggNOG; KOG1399; Eukaryota.
DR   eggNOG; COG2072; LUCA.
DR   GeneTree; ENSGT00760000119232; -.
DR   HOGENOM; HOG000076537; -.
DR   HOVERGEN; HBG002037; -.
DR   InParanoid; P31513; -.
DR   KO; K00485; -.
DR   OMA; QVIKGTC; -.
DR   OrthoDB; EOG091G0465; -.
DR   PhylomeDB; P31513; -.
DR   TreeFam; TF105285; -.
DR   BioCyc; MetaCyc:HS00223-MONOMER; -.
DR   BRENDA; 1.14.13.148; 2681.
DR   BRENDA; 1.14.13.8; 2681.
DR   Reactome; R-HSA-217271; FMO oxidises nucleophiles.
DR   SABIO-RK; P31513; -.
DR   GeneWiki; Flavin_containing_monooxygenase_3; -.
DR   GenomeRNAi; 2328; -.
DR   PRO; PR:P31513; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000007933; -.
DR   CleanEx; HS_FMO3; -.
DR   ExpressionAtlas; P31513; baseline and differential.
DR   Genevisible; P31513; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; TAS:ProtInc.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:InterPro.
DR   GO; GO:0004497; F:monooxygenase activity; IBA:GO_Central.
DR   GO; GO:0004499; F:N,N-dimethylaniline monooxygenase activity; TAS:Reactome.
DR   GO; GO:0050661; F:NADP binding; IEA:InterPro.
DR   GO; GO:0034899; F:trimethylamine monooxygenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0055114; P:oxidation-reduction process; IBA:GO_Central.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   Gene3D; 3.50.50.60; -; 2.
DR   InterPro; IPR012143; DiMe-aniline_mOase.
DR   InterPro; IPR023753; FAD/NAD-binding_dom.
DR   InterPro; IPR000960; Flavin_mOase.
DR   InterPro; IPR020946; Flavin_mOase-like.
DR   InterPro; IPR002255; Flavin_mOase_3.
DR   Pfam; PF00743; FMO-like; 1.
DR   PIRSF; PIRSF000332; FMO; 1.
DR   PRINTS; PR00370; FMOXYGENASE.
DR   PRINTS; PR01123; FMOXYGENASE3.
DR   SUPFAM; SSF51905; SSF51905; 2.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Endoplasmic reticulum; FAD; Flavoprotein; Membrane; Microsome;
KW   Monooxygenase; NADP; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transmembrane.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:9224773}.
FT   CHAIN         2    532       Dimethylaniline monooxygenase [N-oxide-
FT                                forming] 3.
FT                                /FTId=PRO_0000147654.
FT   NP_BIND       9     14       FAD. {ECO:0000255}.
FT   NP_BIND     191    196       NADP. {ECO:0000255}.
FT   MOD_RES     401    401       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97501}.
FT   VARIANT      24     24       E -> D (modest increase in catalytic
FT                                efficiency toward trimethylamine,
FT                                methimazole, ethylenethiourea and
FT                                sulindac). {ECO:0000269|PubMed:17050781}.
FT                                /FTId=VAR_042705.
FT   VARIANT      32     32       E -> K (in TMAU; dbSNP:rs72549320).
FT                                {ECO:0000269|PubMed:12893987}.
FT                                /FTId=VAR_037306.
FT   VARIANT      52     52       A -> T (in TMAU; dbSNP:rs72549321).
FT                                {ECO:0000269|PubMed:10479479}.
FT                                /FTId=VAR_008146.
FT   VARIANT      61     61       N -> K (loss of activity).
FT                                {ECO:0000269|PubMed:17050781}.
FT                                /FTId=VAR_042706.
FT   VARIANT      61     61       N -> S (in TMAU; more than 90% reduction
FT                                in catalytic efficiency toward
FT                                trimethylamine, benzydamine and methyl p-
FT                                tolyl sulfide; dbSNP:rs72549322).
FT                                {ECO:0000269|PubMed:11191884,
FT                                ECO:0000269|PubMed:17531949}.
FT                                /FTId=VAR_037307.
FT   VARIANT      66     66       M -> I (in TMAU; loss of activity;
FT                                affects FAD binding; dbSNP:rs72549323).
FT                                {ECO:0000269|PubMed:10338091,
FT                                ECO:0000269|PubMed:17531949,
FT                                ECO:0000269|PubMed:9536088}.
FT                                /FTId=VAR_002423.
FT   VARIANT     132    132       D -> H (in dbSNP:rs12072582).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_015364.
FT   VARIANT     153    153       P -> L (in TMAU; 90% reduction in
FT                                catalytic efficiency toward
FT                                trimethylamine and benzydamine; 34%
FT                                reduction in catalytic efficiency toward
FT                                methyl p-tolyl sulfide; nearly no effect
FT                                on affinity for these substrates;
FT                                dbSNP:rs72549326).
FT                                {ECO:0000269|PubMed:11191884,
FT                                ECO:0000269|PubMed:17531949,
FT                                ECO:0000269|PubMed:9536088}.
FT                                /FTId=VAR_002424.
FT   VARIANT     158    158       E -> K (35%, 45% and 71% increase in
FT                                catalytic efficiency toward
FT                                trimethylamine, benzydamine and methyl p-
FT                                tolyl sulfide, respectively;
FT                                dbSNP:rs2266782).
FT                                {ECO:0000269|PubMed:10479479,
FT                                ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|PubMed:17050781,
FT                                ECO:0000269|PubMed:17531949,
FT                                ECO:0000269|PubMed:9536088,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_002425.
FT   VARIANT     198    198       D -> E (in dbSNP:rs529940450).
FT                                {ECO:0000269|PubMed:15618753}.
FT                                /FTId=VAR_018345.
FT   VARIANT     205    205       R -> C (in dbSNP:rs28363549).
FT                                {ECO:0000269|PubMed:15618753,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018346.
FT   VARIANT     257    257       V -> M (65% increase in catalytic
FT                                efficiency toward trimethylamine and 60%
FT                                reduction toward benzydamine and methyl
FT                                p-tolyl sulfide; dbSNP:rs1736557).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17050781,
FT                                ECO:0000269|PubMed:17531949,
FT                                ECO:0000269|PubMed:9536088,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_002426.
FT   VARIANT     277    277       V -> A (in dbSNP:rs2066530).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014845.
FT   VARIANT     308    308       E -> G (16% reduction in catalytic
FT                                efficiency toward trimethylamine and 40%
FT                                increase toward benzydamine and methyl p-
FT                                tolyl sulfide; dbSNP:rs2266780).
FT                                {ECO:0000269|PubMed:10479479,
FT                                ECO:0000269|PubMed:17050781,
FT                                ECO:0000269|PubMed:17531949,
FT                                ECO:0000269|PubMed:9536088,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_002427.
FT   VARIANT     360    360       L -> P (in dbSNP:rs28363581).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_015365.
FT   VARIANT     362    362       E -> Q (in dbSNP:rs2066532).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014846.
FT   VARIANT     387    387       R -> L (in TMAU; dbSNP:rs72549331).
FT                                {ECO:0000269|PubMed:10479479}.
FT                                /FTId=VAR_008147.
FT   VARIANT     416    416       K -> N (2-fold decrease in affinity for
FT                                trimethylamine; 3-fold decrease in
FT                                catalytic efficiency toward methimazole;
FT                                3-fold increase in catalytic efficiency
FT                                toward sulindac; 30% increase in
FT                                catalytic efficiency toward
FT                                ethylenethiourea; dbSNP:rs774785217).
FT                                {ECO:0000269|PubMed:17050781}.
FT                                /FTId=VAR_042707.
FT   VARIANT     434    434       M -> I (in TMAU; profoundly alters enzyme
FT                                function; dbSNP:rs72549332).
FT                                {ECO:0000269|PubMed:11191884}.
FT                                /FTId=VAR_037308.
FT   VARIANT     492    492       R -> W (in TMAU; loss of activity;
FT                                affects FAD binding; dbSNP:rs72549334).
FT                                {ECO:0000269|PubMed:10338091,
FT                                ECO:0000269|PubMed:11191884,
FT                                ECO:0000269|PubMed:17531949}.
FT                                /FTId=VAR_008145.
FT   VARIANT     503    503       G -> R (in dbSNP:rs72549335).
FT                                {ECO:0000269|PubMed:12527699}.
FT                                /FTId=VAR_015366.
FT   CONFLICT    298    298       S -> T (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    369    369       I -> L (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    400    405       PSMEDM -> GPFYGKTL (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    410    410       N -> I (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    418    419       KW -> ANG (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    444    445       KP -> T (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    449    449       W -> M (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    454    454       D -> G (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    461    462       VY -> L (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    478    478       Q -> S (in Ref. 1; AAA86284).
FT                                {ECO:0000305}.
FT   CONFLICT    486    486       I -> M (in Ref. 2; CAA87632).
FT                                {ECO:0000305}.
SQ   SEQUENCE   532 AA;  60033 MW;  729E41D53EFC4110 CRC64;
     MGKKVAIIGA GVSGLASIRS CLEEGLEPTC FEKSNDIGGL WKFSDHAEEG RASIYKSVFS
     NSSKEMMCFP DFPFPDDFPN FMHNSKIQEY IIAFAKEKNL LKYIQFKTFV SSVNKHPDFA
     TTGQWDVTTE RDGKKESAVF DAVMVCSGHH VYPNLPKESF PGLNHFKGKC FHSRDYKEPG
     VFNGKRVLVV GLGNSGCDIA TELSRTAEQV MISSRSGSWV MSRVWDNGYP WDMLLVTRFG
     TFLKNNLPTA ISDWLYVKQM NARFKHENYG LMPLNGVLRK EPVFNDELPA SILCGIVSVK
     PNVKEFTETS AIFEDGTIFE GIDCVIFATG YSFAYPFLDE SIIKSRNNEI ILFKGVFPPL
     LEKSTIAVIG FVQSLGAAIP TVDLQSRWAA QVIKGTCTLP SMEDMMNDIN EKMEKKRKWF
     GKSETIQTDY IVYMDELSSF IGAKPNIPWL FLTDPKLAME VYFGPCSPYQ FRLVGPGQWP
     GARNAILTQW DRSLKPMQTR VVGRLQKPCF FFHWLKLFAI PILLIAVFLV LT
//
